Biopharmaceutical Development: Innovations Impacting Development
BioPharm International® spoke with Oury Chetboun, CEO of Seekyo Therapeutics, to get his perspective on what impact new modalities and technology innovations are having on biopharmaceutical development.
The biopharma industry is seeing growth in innovation with new treatments for cancer and autoimmune diseases and the development of specialized medicines. New technologies, such as artificial intelligence and machine learning, are also having an impact on drug development and manufacturing.
New drugs come with the cost to develop and produce before they can reach patients. According to Oury Chetboun, CEO of Seekyo Therapeutics, one trend that is advancing the biopharma industry is continuous manufacturing, which can reduce time to market. “You may have a fantastic drug [in the lab] which costs [a] massive [amount] to be scaled up, but if you can't get that into a large-scale production or at a reasonable cost, then you can't do anything,” Chetboun cautions.
Click the video above to watch the full interview.
About the speaker
Oury Chetboun is CEO of Seekyo Therapeutics. He has a background in immunology and has been working in business development for 20 years. Seekyo develops solid cancer treatments that target functional proteins.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
